These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30372367)

  • 41. Over-the-counter medications for acute cough in children and adults in ambulatory settings.
    Smith SM; Schroeder K; Fahey T
    Cochrane Database Syst Rev; 2008 Jan; (1):CD001831. PubMed ID: 18253996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Antenatal ambroxol administration for prevention of respiratopry distress syndrome in preterm infants: preliminary report].
    Marinov B; Jekova N; Andreeva A; Hitrova S
    Akush Ginekol (Sofiia); 2011; 50(4):17-22. PubMed ID: 22479892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Over-the-counter medications for acute cough in children and adults in ambulatory settings.
    Schroeder K; Fahey T
    Cochrane Database Syst Rev; 2001; (3):CD001831. PubMed ID: 11686998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical research on high-dosage ambroxol hydrochloride associated with ulinastatin in improvement of lung tissue injury of patients with paraquat poisoning].
    Wang WS; Guan JY; Lu QL
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2010 Jan; 28(1):58-60. PubMed ID: 20426988
    [No Abstract]   [Full Text] [Related]  

  • 45. [The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients].
    Jahnz-Rózyk K; Kucharczyk A; Chciałowski A; Płusa T
    Pol Merkur Lekarski; 2001 Sep; 11(63):239-43. PubMed ID: 11761819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lack of effect of ambroxol, a bronchial secretolytic agent, on gastric mucus in man.
    Guslandi M; Zanoni ME
    J Int Med Res; 1985; 13(5):281-3. PubMed ID: 4054429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Ambroxol].
    Akkoca Yildiz O
    Tuberk Toraks; 2006; 54 Suppl 1():3-14. PubMed ID: 17089236
    [No Abstract]   [Full Text] [Related]  

  • 48. [Use of mucolytic preparations (Mucosolvan) in selected diseases of the upper respiratory tract. Part II].
    Szmeja Z; Golusiński W; Mielcarek-Kuchta D; Laczkowska-Przybylska J
    Otolaryngol Pol; 1997; 51(5):480-6. PubMed ID: 9557050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Topical ambroxol for the treatment of neuropathic pain: A first clinical observation. German version].
    Kern KU; Weiser T
    Schmerz; 2015 Dec; 29(6):632-40. PubMed ID: 26597641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion.
    Tang W; Zhu D; Wu F; Xu JF; Yang JP; Deng ZP; Chen XB; Papi A; Qu JM
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5119-5127. PubMed ID: 37318485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Ambroxol-induced toxicoderma].
    Saad N; Guillot I; Vautrin C; Freymond N; Catelain A; Kerhoas A; Nicolas JF
    Ann Dermatol Venereol; 2006 Feb; 133(2):181-2. PubMed ID: 16508607
    [No Abstract]   [Full Text] [Related]  

  • 52. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease.
    Duijvestijn YC; Mourdi N; Smucny J; Pons G; Chalumeau M
    Cochrane Database Syst Rev; 2009 Jan; (1):CD003124. PubMed ID: 19160217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood.
    Paleari D; Rossi GA; Nicolini G; Olivieri D
    Expert Opin Drug Discov; 2011 Nov; 6(11):1203-14. PubMed ID: 22646987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of respiratory distress syndrome in preterm infants by antenatal ambroxol: a meta-analysis of randomized controlled trials.
    Zhang ZQ; Wu QQ; Huang XM; Lu H
    Am J Perinatol; 2013 Aug; 30(7):529-36. PubMed ID: 23229957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.
    Dal Negro R; Pozzi E; Cella SG
    Pulm Pharmacol Ther; 2018 Dec; 53():80-85. PubMed ID: 30352285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
    Disse B
    Novartis Found Symp; 2002; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pharmacologic approach to airway clearance: mucoactive agents.
    Rubin BK
    Paediatr Respir Rev; 2006; 7 Suppl 1():S215-9. PubMed ID: 16798570
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effect of mucolytic therapy on the production of reactive oxygen species in the blood of patients with an exacerbation of chronic obstructive pulmonary disease].
    Farkhutdinov UR; Farkhutdinov RR; Petriakov VV; Farkhutdinov ShU; Mirkhaĭdarov AM
    Ter Arkh; 2010; 82(3):29-32. PubMed ID: 20564918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential modulation of IgE-dependent activation of human basophils by ambroxol and related secretolytic analogues.
    Gibbs BF
    Int J Immunopathol Pharmacol; 2009; 22(4):919-27. PubMed ID: 20074455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.